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ABSTRACT: Inflammation occurring within the transplanted organ from the time of
harvest is an important stimulus of early alloimmune reactivity and promotes chronic
allograft rejection. Chronic immune-mediated injury remains the primary obstacle to the
long-term success of organ transplantation. However, organ transplantation represents a
rare clinical setting in which the organ is accessible ex vivo, providing an opportunity to
use nanotechnology to deliver therapeutics directly to the graft. This approach facilitates
the directed delivery of immunosuppressive agents (ISA) to target local pathogenic
immune responses prior to the transplantation. Here, we have developed a system of
direct delivery and sustained release of mycophenolate mofetil (MMF) to treat the
donor organ prior to transplantation. Perfusion of a donor mouse heart with MMF-
loaded PEG−PLGA nanoparticles (MMF-NPs) prior to transplantation abrogated
cardiac transplant vasculopathy by suppressing intragraft pro-inflammatory cytokines
and chemokines. Our findings demonstrate that ex vivo delivery of an ISA to donor
organs using a nanocarrier can serve as a clinically feasible approach to reduce transplant
immunity.
KEYWORDS: nanodelivery, transplant, mycophenolate mofetil, chronic rejection, selective drug delivery
Solid organ transplantation has become a mainstay oftreatment for patients with end-stage organ failure. Overthe past decades, the use of increasingly potent
immunosuppressive agents (ISAs) has reduced overall rates of
acute transplant rejection and improved short-term graft
survival. However, long-term transplant outcomes have failed
to improve to the same degree.1,2 Furthermore, in addition to
organ toxicity, ISAs are a significant contributor to several post-
transplantation complications, including infection, cardiovascu-
lar disease, diabetes, and malignancy.3−5 Attempts to minimize
ISAs, such as cyclosporine and tacrolimus, have had mixed
success and are associated with increased risk of acute transplant
rejection.3,6,7
Inflammatory responses occurring within the allograft early in
the post-transplantation period significantly enhance alloim-
munity.8,9 Intragraft inflammation begins prior to organ
procurement, when upregulation of inflammatory cytokines
and adhesion molecules within donor organs occurs simulta-
neously with brain death.10 This process peaks in the
postanastomosis period, coincident with extensive ischemia-
reperfusion injury (IRI). IRI leads to activation of intragraft
antigen-presenting cells, including dendritic cells (DCs).11,12
DCs activated by intragraft inflammation, in turn, promote
alloreactive T cell responses, enhancing chronic alloimmune
injury.11−13 Therefore, the development of more effective
strategies to control early immune-activating events within the
organ and improve long-term transplant outcomes remains a
major focus of investigation in transplantation.
Notable progress in synthesizing and characterizing nanoscale
materials has sparked interest in refining the methods of drug
delivery, especially in the field of oncology.14,15 Nanotechnology
has been used to improve pharmacokinetic profiles, leading to
controlled, sustained release of an agent and its delivery to the
site of interest.16−20 In contrast to most models of systemic
disease, transplantation is a unique scenario, in which the
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affected organ is accessible for intraorgan delivery of
therapeutics. Targeted delivery of nanoparticle-based therapeu-
tics holds significant potential to improve treatment efficacy and
reduce the off-target toxicity that plagues the clinical manage-
ment of transplant recipients.
Mycophenolate mofetil (MMF) blocks inosine mono-
phosphate dehydrogenase and inhibits purine metabolism in
lymphocytes, preventing their proliferation. It is one of the most
commonly used immunosuppressive agents following trans-
plantation and has an excellent safety profile.21 We have
Figure 1. Cellular uptake and organ delivery of PEG−PLGA nanoparticles in vivo and in vitro. (A)HUVECwere used to assess uptake of CF660-
labeled PEG−PLGA nanoparticles (CF660-NP, red). Lysosomes were stained by LysoTracker (green) dye, and cell nuclei were stained using
DAPI (blue). Fluorescence confocal imaging of the HUVEC 1 h postincubation with CF660-NP showed significant uptake. CF660-NPs were
detected inside HUVEC. (B) Histogram of FACS analysis showed a high count of CF660-NPs in HUVEC. (C) No differences were seen in
HUVEC viability at 48 and 72 h incubation compared to control, as assessed by flow cytometry. (D) Mouse heart was perfused with IR800-
labeled PEG−PLGAnanoparticle (IR800-NP) from inferior vena cava (IVC) and immersed in UW (University ofWisconsin) solution for 2 h at
4 °C. (E) Hearts perfused with IR800-NP were imaged by a UVP iBox Explorer imaging microscope, and a strong fluorescent signal was
detected. (F) Hearts perfused with either phospate-buffered saline (PBS) or IR800-NP were transplanted into recipient mice and harvested on
the next day. The heart perfused with IR800-NP showed a strong fluorescent signal in contrast to the PBS-perfused heart. (G) Heart perfused
with IR800-NP (red) was assessed histologically 1 day and 7 days post-transplant. Many IR800-NPs were detected between myocytes (F-actin,
green) at day 1, and IR800-NPs were still detectable 7 days post-transplant. DAPI was used to stain cell nuclei (blue). (H) IR800-NPs were
observed outside the vasculature (CD31, green) at day 1 post-transplant. (I) IR800-NPs were found inside the cytoplasm of CD11b+ cells and
some CD11b− cells at 1 day post-transplant. (J) At day 1 post-transplant, intra-allograft mean fluorescent intensity (MFI) of IR800-NP was
significantly higher in CD11b+ cells compared to that in CD31 (control vsCD31 vsCD11b, 1.1± 0.01 vs 10.4± 0.5 vs 59.8± 2.6, ***p < 0.001,
n = 3/group).
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engineered a nanoparticle carrier of MMFwith excellent loading
and release capacity. Herein, we tested the hypothesis that
preperfusion of the donor heart with MMF-loaded PEG−PLGA
nanoparticles (MMF-NPs) reduces early intragraft inflamma-
tion and prevents cardiac transplant vasculopathy and fibrosis.
RESULTS
Uptake of PLGA Nanoparticles by Human Umbilical
Vein Endothelial Cells. To assess the effect of perfusion with
PEG−PLGA NPs (size: 65 nm) on endothelial cells, we first
measured their uptake by human umbilical vein endothelial cells
(HUVEC) as a model of endothelium.22,23 PEG−PLGA
nanoparticles labeled with CF660 dye (CF660-NPs, red
fluorescence) were incubated with HUVEC for 1 h. Lysosomes
were stained using LysoTracker (green) dye, and images were
taken by confocal microscopy. CF660-NPs were detected
outside of lysosomes and located around the nuclei of
HUVEC (Figure 1A). Intracellular CF660-NPs were counted
by flow cytometry, which confirmed the uptake of CF660-NP by
HUVEC within 1 h of incubation (Figure 1B). To assess if NPs
had an effect on HUVEC viability, NPs were incubated with
HUVEC for 48 and 72 h. FACS analysis of the cells showed that,
even after 72 h of incubation, NPs did not cause any cell death
(Figure 1C).
In Vivo Perfusion of Heart with PEG−PLGA Nano-
particles. To study the kinetics of nanoparticles (NPs)
Figure 2. Synthesis and characterization of MMF-NP. (A) Schematic of MMF-NP fabrication. (B) Dynamic light scattering measurements of
MMF-NP. (C) Transmission electron microscopy image of NPs (stained with 3% uranyl acetate). (D) HUVEC viability incubated with MMF-
NP showed no difference in 24, 48, and 72 h compared to control. (E) In vitro release profile of MMF from NP. (F) T cell stimulation assay
either with control, free MMF, or MMF-NP (freshly prepared, 7 days, and 14 days post-MMF release experiment). MMF-NP suppressed T cell
proliferation, as measured by thymidine incorporation, with no differences between fresh, 7 days and 14 days post-MMF release.
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following delivery to the heart, we synthesized PLGA NPs
loaded with IR800 CW (IR800-NP). IR800 CW is a near-
infrared (NIR) fluorophore.
Mice underwent thoracotomy, and the heart was perfused
with IR800-NP via injection into the inferior vena cava. The
heart was then harvested and immersed in UW (University of
Wisconsin) solution at 4 °C for 2 h (Figure 1D), and it was
imaged using an iBox Explorer2 imaging microscope (UVP).
The fluorescent signal detected from the entire heart organ
demonstrated uniform perfusion of heart tissue with IR800-NP
(Figure 1E).
Next, to assess the trafficking of NP following transplantation,
a heart perfused with IR800-NP as described above was
transplanted into C57BL/6 mouse.24,25 At day 1 post-trans-
plantation, an IR800 fluorescent signal was detectable from the
transplanted heart perfused with IR800-NP, as compared to a
heart perfused with phosphate-buffered saline (PBS) (Figure
1F).
Mice were sacrificed at day 1 and day 7 postcardiac transplant,
and immunofluorescence analysis of the allograft revealed the
presence of IR800-NP (red) within the cardiac tissue (green, F-
actin) at both time points (Figure 1G). We next examined the
distribution of IR800-NPs in vascular and nonvascular compart-
ments of the cardiac allograft. Co-staining with CD31 and
CD11b demonstrated that the vast majority of IR800-NPs were
located within CD11b+ cells (Figure 1H−J).
Figure 3. Biodistribution of MPA*-NP. (A) Heart perfused with MPA*-NPs showed high signal in the whole image and cross-sectional image
compared to the heart perfused with PBS. (B) Schematic describes two group study designs. MPA*-NP was injected intravenously into
recipient mice in the IVMPA*-NP group. MPA*-NP was perfused into the donor heart, and the perfused heart was transplanted into recipient
mice in the MPA*-NP perfusion group. (C) Heart allograft in the MPA*-NP perfusion group showed a MPA*-NP signal significantly higher
than that of the heart allograft in the IV MPA*-NP group (IV MPA*-NP group vsMPA*-NP perfusion group, 21401± 1560 vs 29526± 2742,
*p < 0.05, n = 4mice/group). (D) Kidney, liver, and lung harvested from theMPA*-NP perfusion group showed aMPA*-NP signal significantly
lower than that of the IVMPA*-NP group (IVMPA*-NP group vsMPA*-NP perfusion group, 55689± 289 vs 14806± 1810, ***p < 0.001 for
kidney, 56995 ± 788 vs 18375 ± 1995, ***p < 0.001 for liver, 42411 ± 5743 vs 7712 ± 1330, **p < 0.01 for lung, n = 4 mice/group).
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Figure 4. Early intragraft immune response suppression byMMF-NP. (A)H&E staining of the heart allografts perfused with PBS (control), free
MMF, or MMF-NP 5 days post-transplantation. No difference in light microscopic evidence of rejection, including cellular infiltration or
vascular injury, was detected in heart grafts among the three groups. (B) No difference of cellular infiltration and vascular appearance score was
found among the three groups (control vs free MMF vsMMF-NP, 0.50± 0.12 vs 0.32± 0.61 vs 0.45± 0.07 for cellular infiltration, 0.65± 0.13
vs 0.53 ± 0.14 vs 0.45 ± 0.02 for vascular appearance score, n = 4 mice/group). (C) Analysis of heart allografts by qPCR showed significantly
lower expression of IL-6 and TNFα in the heart grafts perfused with MMF-NP compared to the control and free MMF groups (control vs free
MMF vsMMF-NP, 0.87± 0.05 vs 0.74± 0.13 vs 0.31± 0.10 for IL-6, 0.87± 0.07 vs 0.79± 0.14 vs 0.25± 0.06 for TNFα, n = 4 mice/group).
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Synthesis and Characterization of MMF-Loaded PEG−
PLGA NP (MMF-NP). Mycophenolate mofetil (MMF;
Cellcept) is a prodrug of mycophenolic acid (MPA), an
inhibitor of inosine monophosphate dehydrogenase
(IMPDH). It is routinely used systemically for prevention of
rejection in kidney, liver, and heart transplantation.21,26−28 We
chose MMF to target the organ for pretreatment, due to its
excellent vascular safety profile and lack of end-organ
toxicity.29,30 A mix of polymer and MMF in ethyl acetate was
emulsified in the water phase, followed by solvent evaporation
and MMF-loaded PEG−PLGA NP (MMF-NP) collection by
centrifugation (Figure 2A). The loading efficiency of MMF was
calculated as 23 ± 2.7%, which is equivalent to 39 μg of MMF
per dose. The average size of our MMF-NP was around 60 nm
(Figure 2B), and it was negatively charged (−16.2 ± 0.67) by
dynamic light scattering (DLS) measurement. Observation
under electron microscopy highlighted its round shape, double
layer, and size (Figure 2C).
Kinetics of MMF Release from MMF-NP in Vitro. First,
we tested for toxicity of MMF-NPs on HUVEC. MMF-NPs
were incubated with HUVEC for 24, 48, and 72 h. We did not
observe any toxic effects of MMF-NPs on HUVEC (Figure 2D).
Next, the release profile of MMF fromMMF-NPs was measured
in vitro under physiological conditions. MMF was released
gradually from the NPs during the first 3 days of release,
achieved 60% release by day 7, and the release kinetics remained
controlled through day 10 (Figure 2E).
We then examined the retaining and releasing capacity of
MMF from MMF-NPs by testing its ability to suppress T cell
proliferation in vitro. We compared MMF-NPs to the same
amount of free MMF (39 μg). MMF-NPs and free MMF
suppressed T cell proliferation equally (Figure 2F). To assess
the clinical applicability of this approach, we were also interested
in examining the retention of MMF and testing its
immunosuppressive capacity following long storage. MMF-
NPs, which were stored for 7 and 14 days, were washed
thoroughly and added to a T cell suppression assay. MMF-NPs
from both time points showed effective suppression of T cells
(Figure 2F), demonstrating the stability of these NP over time.
Biodistribution of Labeled MPA Following Intraorgan
Perfusion. To observe the distribution of our NP in vivo, we
used a labeled form of MPA to generate fluorescent NPs. For
these experiments, we utilized MPA, instead of its pro-drug
MMF, as MPA can be conjugated easily with amine-containing
dyes to enable tracking in vivo. We labeled MPA directly with an
amine-functionalized fluorescent dye (amine CF594) (MPA*)
and synthesized NPs (MPA*-NPs).
To assess our ability to detect MPA*-NPs in tissue, hearts
were perfused either with PBS or MPA*-NPs, harvested, and
immersed in UW solution for 2 h. The heart perfused with
MPA*-NPs showed a strong fluorescent signal in both whole
heart and cross-sectional images, as compared to the PBS group
(Figure 3A).
Next, we wanted to assess the degree of accumulation of
MPA* in the heart allograft when the donor allograft is perfused
withMPA*-NP prior to transplant (MPA*-NP perfused group),
as compared to transplanting the recipient with a nonperfused
heart, and then treating the recipient with systemic intravenous
MPA*-NP at the time of transplantation (IV MPA*-NP group)
(Figure 3B). Six hours after heart transplantation, organs from
transplanted animals were harvested for bioluminescence study
to assess the biodistribution of MPA*-NP. Transplanted hearts
from the MPA*-NP perfused group showed a fluorescent signal
significantly higher than that of the heart grafts from the IV
MPA*-NP group (Figure 3C). Other organs, such as kidney,
liver, and lung, revealed greater accumulation of MPA*-NP and
a MFI in recipients from the IV MPA*-NP group significantly
higher than that of the MPA*-NP perfused group (Figure 3D).
These data indicate that MPA was delivered to the donor heart
effectively with perfusion prior to organ transplantation and
remained localized, without accumulation in other organs.
Suppression of Early Intragraft Alloimmune Response
by MMF-NP. Our next objective was to examine the in vivo
efficacy of MMF-NP in a MHC class II mismatch mouse heart
transplant model of chronic allograft rejection. A BM12 mouse
heart (donor heart) was perfused with either PBS (control), free
MMF, orMMF-NP, harvested, and immersed in UW solution at
4 °C. Two hours later, the heart was transplanted into a C57BL/
6 mouse (recipient).
Based on the findings from our previous experiment
evaluating the tempo of MMF release from the NP (refer
Figure 2E), we harvested heart allografts at day 5 post-
transplantation. As expected in this model of chronic allograft
rejection, no difference in cellular infiltration or vascular
appearance of the heart grafts between the groups on day 5
was observed, as assessed by scoring of H&E images the
modified ISHLT score (Figure 4A,B). However, analysis of
heart allografts by qRT-PCR revealed that the allografts perfused
with MMF-NP had significantly lower expression of pro-
inflammatory cytokines, such as IL-6 and TNFα, in comparison
to that of control and free MMF-treated grafts (Figure 4C).
Heart allografts perfused with MMF-NP also demonstrated
lower expression of other pro-inflammatory cytokines, such as
IFNγ, IL-17, and IL-2, but these differences did not reach
significance (data not shown). In addition, intragraft expression
of chemokines was also assessed by qRT-PCR. Significant
reductions in the expression of CXCL9 was observed in the
heart allografts perfused with MMF-NP, as compared to control
and freeMMF (Figure 4D). Treatment with bothMMF-NP and
free MMF also led to a significant decrease in expression of
Figure 4. continued
(D) Expression of CXCL9 was reduced significantly in the heart allograft perfused with MMF-NP, as compared to the control and free MMF
groups (control vs free MMF vsMMF-NP, 0.91± 0.20 vs 1.03± 0.18 vs 0.45± 0.06 for CXCL9, n = 4 mice/group). A trend toward reduction
was also observed for the expression of CCR5 and CXCR3 in theMMF-NP group (control vs free MMF vsMMF-NP, 0.91± 0.09 vs 0.92± 0.12
vs 0.55± 0.10 for CCR5, 1.11± 0.12 vs 0.68± 0.11 vs 0.40± 0.11 for CXCR3, n = 4mice/group). (E)H&E staining of the heart allografts at 14
days post-transplant. Control heart showed moderate cellular infiltration of the myocytes and vasculopathy. Mild cellular infiltration of the
myocytes and clear vasculature were observed in free MMF group. The heart graft perfused with MMF-NP had scant cellular infiltration of
myocytes and clear vasculature. (F) Heart allograft perfused with MMF-NP showed significantly lower cellular infiltration and vascular
appearance compared to that with the control group (control vs free MMF vs MMF-NP, 1.67 ± 0.33 vs 1.41 ± 0.34 vs 0.48 ± 0.13 for cellular
infiltration, 2.52 ± 0.74 vs 1.31 ± 0.19 vs 0.72 ± 0.13 for vascular appearance score, n = 3−4 mice/group). (G) Very few CD3+ T cells and
CD11b+ cells infiltrates were observed in the heart allograft perfused withMMF-NP, as compared to that with the control and freeMMF groups.
ACS Nano Article
DOI: 10.1021/acsnano.9b05115
ACS Nano XXXX, XXX, XXX−XXX
F
Figure 5. Perfusion of donor heart with MMF-NP prior to transplant showed marked effect within the graft and abrogated chronic allograft
vasculopathy. (A) H&E staining of the heart allografts at 28 days post-transplant. Control heart contained moderate to severe cellular
infiltration and occluded vasculature. The heart graft perfused with free MMF contained moderate cellular infiltration and vasculopathy. The
heart graft perfused with MMF-NP contained much lower cellular infiltration and intact vasculature. (B) Histological scoring of both cellular
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CCR5 and CXCR3 as compared to expression of the control,
although no difference was seen between the two MMF
formulations (Figure 4D).
On the basis of our findings that MMF-NP suppresses T cell
proliferation up to 14 days in vitro, we next assessed the status of
heart grafts at 14 days post-transplantation. Heart allografts in all
three groups (control, free MMF, and MMF-NP) were beating
at 14 days post-transplant when they were harvested for analysis.
Histologic assessment revealedmoderate cellular infiltration and
vasculopathy in the control group, whereas those perfused with
free MMF had mild cellular infiltration and clear vasculature
(Figure 4E). Furthermore, heart grafts in the MMF-NP group
had little cellular infiltration of the myocytes and clear
vasculature (Figure 4E). Consequently, grafts perfused with
MMF-NP showed scores for cellular infiltration and vascular
pathology significantly lower than those of the control, but these
differences did not reach statistical significance in comparison
with the free MMF group (Figure 4F). Immunofluorescent
staining revealed fewer CD3+ T cells and CD11b+ cells in heart
allografts perfused with MMF-NP, as compared to control and
free MMF-perfused hearts (Figure 4G).
Pretransplant Donor Heart Perfusion with MMF-NP
Abrogates Cardiac Transplant Vasculopathy. Using this
MHC class II mismatch model of chronic rejection, we next
performed longer-term observation of the allografts to assess the
effect of MMF-NP perfusion at the time of allograft retrieval. At
28 days post-transplant, we harvested the heart allografts,
spleens, and draining lymph nodes (DLNs) of recipient mice
whose grafts were perfused with either PBS (control), free
MMF, or MMF-NP prior to transplantation. All heart allografts
were beating at 28 days post-transplant, but the strength of
contraction of hearts in the control and free MMF groups were
weaker than that in the MMF-NP-treated group. Histologic
analysis of the heart allografts in the control group revealed
moderate to severe cellular infiltration and occluded vasculature
(Figure 5A). In comparison to their appearance at 14 days post-
transplantation (refer to Figure 4E, free MMF), by day 28, the
heart allografts perfused with free MMF showed progressive
graft injury with moderate cellular infiltration and vasculopathy
(Figure 5A). In comparison, allografts perfused with MMF-NP
showed much lower cellular infiltration and intact vasculature,
consistent with less severe injury (Figure 5A), and their
histological appearances were similar to those harvested at day
14 (refer to Figure 4E, MMF-NP). We observed significantly
lower scores for both cellular infiltration and vascular
appearance in the MMF-NP group in comparison to the control
and free MMF groups (Figure 5B), which supported the
observations of H&E-stained tissue. The immunofluorescence
staining of heart allografts also contained lower infiltration of
CD3+ T cells and CD11b+ cells in the MMF-NP group, as
compared to the control and free MMF groups (Figure 5C).
Interstitial fibrosis is an important feature of chronic allograft
injury.31,32 The heart allografts treated withMMF-NP contained
significantly less fibronectin staining, as compared to that of the
control and free MMF groups (Figure 5D). Furthermore, the
gene expression of fibronectin in allograft hearts was significantly
lower in theMMF-NP group (Figure 5E). We also measured the
development of donor-specific antibody (DSA) to assess the
chronic alloimmune response. Serum samples collected at day
28 post-transplant were analyzed by FACS to detect DSA-IgG.
As shown in Figure 5F, serum collected from the MMF-NP
group demonstrates DSA-IgG development significantly lower
than that of other groups. We also evaluated chronic allograft
vasculopathy (CAV).33 Elastica van Gieson stain of heart
allografts harvested on day 28 showed a significant increase of
intimal thickness in control and free MMF-treated recipients
(white arrows). However, the vasculature in those treated with
MMF-NP showed less intimal thickening (Figure 5G).
The expression of VCAM, ICAM, and P-selectin on
endothelium has also been used to assess vasculopathy.33,34
We next assessed the expression of these genes in allograft hearts
and observed a significant suppression of VCAM and P-selectin
expression in the MMF-NP group as compared to that of the
control (Figure 5H). To examine the effect of MMF-NP on
endothelial cells in greater detail, we also assessed the level of
VCAM, ICAM, and P-selectin gene expression in vitro, using
HUVEC stimulated with TNFα and incubated with either free
MMF or MMF-NP. Whereas the expression of these genes was
very low in untreated HUVEC, we noted a marked increase
following stimulation with TNFα. This increase was markedly
and significantly suppressed by MMF-NP treatment, as
compared to that of the control group, and additional
suppression was seen in comparison to treatment with free
MMF alone (Figure 5I).
Lack of Systemic Effect of Allograft Preperfusion with
MMF-NP Despite Prolonged Local Effect on Heart
Allograft. Given the superior histological appearance of the
allograft at 28 days post-transplant, we were interested to assess
if graft perfusion with MMF-NP prior to transplantation had an
effect on peripheral immune responses. Spleens and DLNs
harvested on day 28 post-transplant from mice treated with
MMF-NP, free MMF, and control (PBS) were analyzed by flow
Figure 5. continued
infiltration and vascular appearance showed significantly lower scores in the MMF-NP group, as compared to the control and free MMF group
(control vs freeMMF vsMMF-NP, 2.67± 0.30 vs 2.69± 0.17 vs 0.91± 0.28 for cellular infiltration, 4.01± 0.19 vs 4.03± 0.54 vs 1.43± 0.52 for
vascular appearance score, n = 4 mice/group). (C) Very low infiltration of CD3+ and CD11b+ cells was observed in the heart allograft perfused
withMMF-NP in comparison to control and freeMMF groups. (D) Fibronectin staining showed lower fibrosis in MMF-NP group compared to
control and free MMF groups. (E) Gene expression of fibronectin showed significantly lower expression in the allograft heart harvested from
MMF-NP group compared to control and free MMF groups (control vs free MMF vs MMF-NP, 1.2 ± 0.12 vs 0.8 ± 0.04 vs 0.4 ± 0.08, n = 3
mice/group). (F) MFI of DSA-IgG in serum from 28 days post-transplant in the MMF-NP group was significantly less than that in the control
and free MMF groups (control vs free MMF vsMMF-NP, 2914± 156 vs 2532± 194 vs 2043± 79, n = 4 mice/group). (G) Elastica van Gieson
stain of the allograft heart showed thinner intima in the MMF-NP group compared to that in the control and free MMF groups (control vs free
MMF vsMMF-NP, 42.6± 8.4 vs 17.6± 4.1 vs 6.8± 2.4, 2 random arteries from eachmouse, n = 4mice/group). (H)Gene expression of VCAM,
ICAM, and P-selectin in the allograft heart showed significantly lower expression inMMF-NP group compared to control (control vs free MMF
vsMMF-NP, 1.3± 0.1 vs 1.0± 0.1 vs 0.6± 0.1 for VCAM, 0.9± 0.02 vs 0.8± 0.1 vs 0.7± 0.09 for ICAM, 1.2± 0.1 vs 0.8± 0.08 vs 0.6± 0.06 for
P-selectin, n = 3mice/group). (I)HUVEC stimulated by TNFα showed high expression of VCAM, ICAMandP-selectin, whichwere suppressed
by adding MMF-NP to a greater degree than by free MMF (control vs free MMF vsMMF-NP, 13.4± 1.2 vs 10.2± 0.9 vs 8.6± 0.5 for VCAM,
27.4 ± 3.0 vs 15.9 ± 2.3 vs 7.1 ± 1.2 for ICAM, 36.8 ± 2.1 vs 15.7 ± 0.9 vs 10.7 ± 1.2 for P-selectin, n = 3 mice/group).
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cytometry. We observed no differences in the percentages of
CD4+ and CD8+ T cells in spleens or DLN between the three
groups (Supplementary Figure S1A). Similarly, percentages of
CD4+CD62Llow, CD8+CD62Llow, CD4+CD69+, CD8+CD69+,
and CD4+CD25+Foxp3+T cells in the spleen and DLN were not
statistically different among the three groups (Supplementary
Figure S1B).
We then tested the effect of intraorgan delivery on the
peripheral alloimmune responses using Elispot and mixed
lymphocyte reaction (MLR) of spleen and DLN. In Elispot
analysis, we observed no statistically significant differences
between groups in spleen and DLN (Supplementary Figure
S1C). MLR assay also showed no statistically significant
differences between groups in cells harvested from the spleen
or DLN (Supplementary Figure S1D). These findings suggested
that the selective perfusion of heart allografts with MMF-NP
suppressed the local intragraft alloimmune response, but it did
not affect the systemic immune response.
DISCUSSION
The majority of transplanted organs undergo hypothermic
perfusion between procurement and transplantation, which
provides the opportunity to add therapeutic agents, including
nanocarriers, into the preservation fluid. Direct delivery of ISAs
to the organ at the time of transplantation could potentiate their
efficacy by decreasing intragraft inflammation and alloimmune
activation during this critical period. This approach could also
potentially decrease the need for systemic exposure to ISAs, such
as calcineurin inhibitors, which have been implicated in
microvascular toxicity, accelerated cardiovascular disease, and
malignancies.1,35−40
Allograft ischemia, which is unavoidable in transplantation, is
one of the most significant stimuli of intragraft inflammation.
Several noteworthy studies have emphasized the importance of
intragraft immune activation in orchestrating allograft rejec-
tion.41−43 Intragraft inflammatory responses can lead to
increased alloimmunity via activation of resident dendritic
cells.12,13,44−50 Early innate inflammatory responses have been
found to be regulated critically by IFNγ-producing endogenous
CD8+ T cells present in the recipient before detectable priming
of alloantigen T cells.51,52 We have recently reported that early
ischemic injury to the organ leads to increased intragraft IL-6
production, thereby enhancing alloimmunity. Furthermore,
perfusing organs with nanocarriers of anti-IL-6 prior to
transplantation significantly improved transplant outcomes in
a murine model of cardiac transplantation.12
T cells can be directly primed and stimulated by activated
endothelial cells expressing adhesion molecules, along with class
I and II MHC molecules.50,53−60 Furthermore, endothelial cells
may also play a role in recruiting recipient antigen-presenting
cells (APC) to the organ,61−64 indicating their central role in
orchestrating early alloimmune responses. Recognizing the
therapeutic potential of targeted intraorgan drug delivery in
transplantation, several other groups have also applied nano-
technology to deliver therapeutics to the endothelium in organs
for transplant. Ex vivo machine perfusion has been used to
deliver therapeutics to human kidneys and blood vessels prior to
transplant and led to a reduction in intragraft activated T
cells.22,23,65 These studies together emphasize the impact of the
intragraft immune response in the pathogenesis of graft rejection
and highlight the importance of engineering therapies aimed at
disrupting its development.
In clinical practice, MMF and MPA are routinely and
interchangeably used in organ transplantation, due to both
efficacy and vascular and metabolic safety profile.21,66 We chose
MMF for our NP for delivery to the heart allograft, as it has lower
polarity than MPA because of the masking of polar carboxylic
groups, which leads to higher loading efficiency in emulsification
as well as slower release kinetics from the NP that thereby
generate a more effective therapeutic product. MMF, a prodrug
of MPA, inhibits inosine monophosphate dehydrogenase
(IMPDH), interfering with purine synthesis and proliferation
of lymphocytes.67−69 MMF also blocks glycosylation of
lymphocyte and monocyte glycoproteins required for adhesion
to endothelial cells and inhibits leukocyte recruitment into areas
of inflammation by reducing the expression of adhesion
molecules such as E- and P-selectin.70,71 Therefore, early
application of MMF to harvested organs could target
alloimmune responses on multiple levels.72 Similar to previous
reports,22,23,73 we first assessed the uptake and toxicity of our
PEG−PLGA NP by HUVEC. In keeping with our findings with
other NPs, these studies indicated that MMF-NP had no toxic
effect on HUVEC.We examined the kinetics of release of MMF,
which showed a sustained release pattern, and we demonstrated
the stability of these NP, as both freshly manufactured and
stored MMF-NP suppressed T cell proliferation effectively in
vitro. These data suggest that perfusion of organs prior to
transplant not only suppresses immediate events in alloimmune
activation, but it also could dampen the later phases of chronic
rejection, as well.
We targeted the donor organ through direct perfusion with
IR800-NP prior to transplantation, and we assessed the
distribution of IR800-NP within the organ pre- and post-
transplantation. The perfused heart contained a strong signal
prior to transplantation, and NPs could be distinguished clearly
following transplantation, located between the F-actin filaments
of the perfused heart. Perfused NPs were taken up mainly by
CD11b+ cells, such as macrophages or monocytes. Therefore,
targeted therapies aimed specifically toward macrophages could
be achieved potentially using this approach.
One important issue was to assess the superiority of NPs in
delivering drug to the allograft while avoiding peripheral tissue
accumulation. To answer this question, we generated NPs with
labeled drug and examined the resulting in vivo signal to observe
their distribution. For these labeling experiments, we selected
MPA over MMF due to technical considerations. Unlike MMF,
MPA has a carboxylic acid, which can be conjugated easily with
amine-containing dyes by carboxylamine cross-linking via
carbodiimide-mediated coupling chemistry. MPA labeled with
amine CF594 (MPA*) was placed inside a NP (MPA*-NP) and
perfused to the heart allograft prior to transplant, and we
examined the distribution of its signal in vivo in comparison to
systemic IV administration into recipient mice. As expected,
MPA*-NP-perfused cardiac allografts contained a MPA*-NP
signal higher than that of cardiac allografts exposed only to
MPA*-NP via intravenous injection into the recipient, whereas
the other major organs showed a lower signal in the recipients of
MPA*-NP-perfused hearts. These results clarified the effective-
ness of our selective drug delivery and emphasized the
advantages of this perfusion strategy with respect to avoidance
of off-target effects on other vital organs.
Then, we used a model of chronic allograft rejection, anMHC
class II mismatch murine heart transplant model, to test the
efficacy of MMF-NP in impacting this process at several time
points. This model does not replicate all features of chronic
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rejection observed in humans but demonstrates early features of
vascular injury. Reflecting the insidious development of vascular
allograft injury, cellular infiltrates or vascular injuries were not
prominent at day 5 post-transplantation in any of the treatment
groups. Nonetheless, we examined the mRNA transcripts of
inflammatory cytokines as more sensitive markers of early
inflammatory responses. Significant reductions in IL-6, TNFα,
and IFNγ were observed, along with reductions in key pro-
inflammatory chemokines.74−80 MMF inhibits T lymphocyte
proliferation directly through its classical mechanism of action
and is also known to decrease expression of adhesion molecules
by endothelial cells.70,71 The effect of MMF on endothelial cells
is independent of its effect on nucleotide synthesis.81 MMF
blocks TNFα induced expression of adhesion molecules by
endothelial cells via effects on intracellular signaling pathways,
namely, inhibition of phosphorylation of MAP kinases,
decreased in reactive oxygen species generation, and inhibition
of nuclear translocation of NF-κB p65.82
Our mechanistic data support a role for MMF in decreasing
local inflammation within the graft at the time of transplant, and
these findings suggest that decreased lymphocyte trafficking into
the transplant may be an important mechanism for the observed
improved allograft outcomes.
By day 28 post-transplantation, both the control group and
free MMF groups had much more severe allograft damage than
did the MMF-NP-treated grafts. Immune characterization of T
cells and macrophages also showed a marked reduction in these
cells.
The major characteristics of chronic allograft rejection are
fibrosis and allograft vasculopathy.31−33,83 Although the mouse
model cannot replicate all features of chronic allograft rejection
in humans, in cardiac allografts harvested at 28 days following
transplantation, we observed significantly less fibrosis, lower
expression of VCAM and P-selectin, and lesser degrees of
intimal thickening in the MMF-NP-treated recipients. To more
directly examine the effect of MMF-NP on endothelial cell
activation, we also returned to the in vitro model of TNFα
stimulated HUVEC, incubated either with PBS, free MMF, or
MMF-NP, and we found a significant reduction in the
expression of adhesion molecules after incubation with MMF-
NP, similar to our results in the heart allograft.
Examining the alloimmune responses in the lymphoid tissues
of the host revealed no difference between groups, indicating
that the impact of MMF-NP on allograft injury may be mediated
solely by its effect on intragraft immune activation. Interestingly,
we found lower levels of DSA in MMF-NP treated recipients,
which suggests this treatment may have influenced antibody
generation in the draining LN in addition to its local effects.
Great interest exists currently in the ex vivo perfusion of donor
organs as a strategy to optimize grafts prior to trans-
plantation.23,84−86 The method of static simple cold storage
(SCS) is approved for liver grafts, whereas both SCS and
dynamic hypothermic machine perfusion are clinically approved
for kidneys. The potential to use ISA-loaded nanocarriers (ISA-
NP) for targeted drug delivery has begun to attract considerable
attention in the field of transplantation.12,23,24,87,88 Based on the
model described here, we speculate that perfusing organs with
ISA-NP using currently available perfusion machines could be a
readily translatable strategy that could reduce early intragraft
inflammation significantly, decrease alloimmune activation, and
potentially improve longer-term outcomes. Such findings are
supported by previous publications from others.88,89 By
perfusing the donor graft with NPs loaded with agents to
oppose the pro-inflammatory effects of ischemia prior to
transplantation, the disadvantage of prolonged ischemic time
to transplant outcomes could also be mitigated.
An interesting future direction will be to investigate the
optimal duration of perfusion with NP to maximize ISA delivery
to the transplant organ. Devising a maximally effective strategy
to apply this approach will require further evaluation.
Our strategy allows for the delivery of a wide range of
combinatorial therapeutics other than ISAs, including drugs
ranging from small molecules to antibodies, which underlines its
vast potential therapeutic implications. Given the substantial
clinical unmet needs in transplantation, we believe that
intraorgan delivery of nanotherapeutics prior to transplantation
could lead to substantial improvements in transplantation
outcomes. The FDA has approved the biocompatible and
biodegradable PEG−PLGA polymer used in this study for
clinical applications, and its routine use in medical materials
such as surgical sutures90−94 demonstrates its excellent safety
profile.
CONCLUSIONS
In summary, our current study establishes a method of a
controlled, gradual release of MMF through perfusion of the
allograft, at the time of harvest with MMF-NP. Our data
indicates that perfusion of heart allografts with MMF-NP prior
to transplantation suppresses the early intragraft immune
response and leads to decreased evidence of transplant
vasculopathy and fibrosis post-transplantation.
METHODS
NP Incubation with HUVEC. HUVEC were plated in 4-well
chambered Nunc Lab-Tek II chamber slides overnight. Then, CF660-
NP suspensions were added to different wells and incubated for 1 h in a
humidified 37 °C, 5% CO2 incubator. The cells were washed with PBS
three times and stained with DAPI and Lysotracker (Lysotracker Green
DND-26).
HUVEC Viability Assessment. HUVEC were cultured in 6-well
plates overnight (0.5 × 106 cells/mL). Empty NPs or MMF-NPs were
added to the HUVEC at concentrations similar to what was used in vivo.
The samples were incubated in a humidified 37 °C, 5% CO2 incubator
in triplicates for 24, 48, and 72 h. Cells cultured without any additional
reagent were considered as control. Cells were washed three times with
PBS at the end of incubation time, and dead cells were stained using
eBioscience fixable viability dye eFluor 450 (cat# 65-0863-14). The cell
suspension was analyzed using a FACS Canto II (BD Bioscience,
Franklin Lakes, NJ) instrument.
Preparation and Characterization of MMF-NPs. We have
engineered MMF-NPs using a single emulsion and solvent evaporation
method. Briefly, poly(D,L-lactic-co-glycolic) acid copolymer (PLGA)
was dissolved in ethyl acetate and mixed with MMF (in acetone). The
mix was then emulsified in 3 mL of deionized water using probe
sonication and homogenization over ice. The emulsion was added
dropwise to 20 mL of deionized water and stirred for 2 h to evaporate
the organic solvent. After solvent evaporation, the MMF-NP was
collected and washed by centrifugation using Amicon Ultra-15
centrifugal filter units (MWCO 100 kDa) at 3000g for 30 min. The
size and zeta-potential of MMF-NPs were assessed and characterized
using DLS. The morphology of MMF-NPs was studied using scanning
electron microscopy and transmission electron microscopy. The filtrate
of the MMF-NP wash steps were collected, and the absorbances were
then analyzed at 300 nm using a UV/vis spectrophotometer. The
amount of MMF in the filtrate was quantified by comparing the
absorbance at 300 nmwith a calibration curve of various concentrations
of MMF.
The loading efficiency was calculated as follows:
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loading efficiency (%) (MMFi MMFf)/MMFi= −
where MMFi is the initial amount of MMF used to prepare MMF-NP
and MMFf is the free nonloaded MMF determined in the last step.
Release Profile of MMF from MMF-NP. To quantify the release
profile of MMF from NPs, the MMF-NP solutions were incubated in
triplicates at 37 °C and assessed at defined time intervals (1, 2, and 4 h;
1, 2, 3, 4, 7, and 14 days). The samples were centrifuged at each time
point using Amicon Ultra-15 centrifugal filter units (MWCO 10 kDa;
Sigma-Aldrich) at 3000g for 15 min. The absorbances of the filtrate and
MMF-NP suspension were then analyzed at 300 nm using a UV/vis
spectrophotometer. The amount of released MMF at each time point
was quantified by comparing the absorbance at 300 nm with a
calibration curve of various concentrations of MMF.
T Cell Proliferation Assay. Splenocytes were isolated from the
spleens of C57BL/6 mice and seeded at one million cells per well in a
round-bottom 96-well plate. Next, cells were stimulated using anti-
mouse CD3/CD28 antibodies (3 μg/mL in complete RPMI media).
Free MMF and MMF-NP (freshly prepared, and 7 and 14 days post-
MMF release experiment) were added to the cells. Unstimulated
splenocytes were used as the negative control, and splenocytes
stimulated with anti-mouse CD3/CD28 without the addition of
MMF or MMF-NP were used as the positive control. The plate was
placed in a humidified 37 °C, 5% CO2 incubator for 2 days. Next,
tritiated thymidine (3H) was added to each well, and the plate was
returned to the incubator for 14 h. Cells were harvested using a
semiautomated sample harvester and analyzed using a β scintillation
counter.
Labeling of Mycophenolic Acid.MPA (10 mM) was prepared in
a 4 mL vial dried under high vacuum for 24 h and dissolved in 100 μL of
dimethylformamide (DMF) with (1H-benzotriazol-1-yl)-1,1,3,3-tetra-
methyluronium hexauorophosphate (HBTU) (12 mM, 1.2 equiv). The
solution was stirred at RT under argon for 30 min. Then, the amine-
functionalized dye (amine CF594) dissolved in 200 μL of anhydrous
DMFwith a concentration of 11mMwas added to the reactionmixture.
To activate the coupling reaction, 2 μL of triethylamine (1.2 μmol, 1.2
equiv) was added to the solution and stirred for 4 h. To quench the
reaction, the reaction mixture was directly dried under high vacuum for
2 h. The mixture was diluted with 300 μL of methanol, and 5 μL of
solution was injected into LC/MS (Agilent 1200, USA) with a gradient
reversed phase system (10 to 100% ACN/H2O with 0.1% formic acid
for 20 min) using Phenomenex Luna 5 μm C18(2) column (100 × 4.6
mm, flow rate; 0.7 mL/min, monitoring of absorption; 254, 320, and
600 nm). The labeled MPA product (MPA*) was purified by reversed
phase HPLC (Phenomenex Luna 5 μm C18 (2) column of 250 × 10.0
mm, flow rate; 2 mL/min, monitoring of absorption; 254, 320, and 600
nm) with a gradient solvent system (15% to 75% ACN/H2O with 0.1%
formic acid for 40 min).
Cell Line and Mice. HUVEC (CRL-1730) were purchased from
ATCC. C57BL/6J (JAX#000664) and B6(C)-H2-Ab1bm12/KhEgJ
(BM12, JAX#001162) were obtained from Jackson Laboratory. Male
or female mice were used at 7−8 weeks of age and were housed in
sterilized and ventilated cages in a specific pathogen-free animal facility
under a standard 12 h light/12 h dark cycle. Mice were fed irradiated
food and water ad libitum. Each individual experiment was performed
using three to four mice per group. All animal experiments andmethods
were performed in accordance with the relevant guidelines and
regulations approved by the Institutional Animal Care and Use
Committee of Brigham and Women’s Hospital, Boston, MA.
Mouse Heterotopic Cardiac Transplantation. Vascularized
intra-abdominal heterotopic transplantation of heart allografts was
performed using microsurgical techniques.24,25 One milliliter of cold
heparin (BD Vacutainer sodium heparin #366480, 143USP units/10
mL) was infused into the inferior vena cava (IVC) of the donor mouse.
After heparin perfusion, either PBS (control), free MMF, or MMF-NP
was infused into the heart from the IVC. The heart was harvested
following ligation/dissection of the superior vena cava (SVC) and IVC,
and dissection of ascending aorta and pulmonary artery. Harvested
donor heart was stored at 4 °C and immersed in UW (University of
Wisconsin) solution for 2 h. After abdominal incision of recipient
mouse, abdominal aorta and IVC were clamped. Ascending aorta and
pulmonary artery of donor heart were sutured to abdominal aorta and
IVC of recipient mouse, respectively, using 10−0 suture. Beating of
transplanted heart was observed upon removal of cross clamp, and
abdominal incision was closed by 6−0 suture. The survival of cardiac
allografts was assessed by daily palpation.
Immunohistochemistry and immunofluorescence. Heart
grafts harvested at designated time points post-transplantation were
fixed in formalin and embedded in a paraffin block, or they were
preserved in Optimal Cutting Temperature (OCT) compound
(Tissue-Tek, Torrance, CA) and stored at −80 °C. Samples were cut
into 5 μm sections and stained either withH&E (paraffin block section)
or with DAPI, anti-F-actin, anti-CD31, anti-CD3, anti-CD11b,
fibronectin, VCAM, ICAM, and P-selectin for immunofluorescence
(OCT block section).
Histological Assessment of the Allograft Heart. Histological
evaluation from H&E slides was done using a score modified from the
International Society for Heart and Lung Transplantation.95,96 Cellular
infiltration was graded blindly from 0 to 4 from 6 random microscopic
fields of each heart section (3 sections/heart, 4 mice per group). The
grades were defined as follows: grade 0 (no cellular infiltration), grade 1
(less than 25% cellular infiltration), grade 2 (25 to 50% cellular
infiltration), grade 3 (50 to 75% cellular infiltration), and grade 4 (more
than 75% cellular infiltration with hemorrhage and/or fibrosis).
Vascular appearance was determined by a combination of vascular
occlusion score and perivascular cellular infiltration. Vascular (artery)
occlusion was scored from grade 0 to 3 for every artery (3 sections/
heart, 4 mice per group). The grades were defined as follows: grade 0
(no or minimal occlusion, < 10%), grade 1 (10−25% occlusion), grade
2 (25% to 75% occlusion), and grade 3 (more than 75% occlusion). The
perivascular cellular infiltration was scored as follows: grade 0 (no
cellular infiltration around artery), grade 1 (less than 25% cellular
infiltration around artery), grade 2 (25% to 75% cellular infiltration
around artery), and grade 3 (more than 75% cellular infiltration around
artery). Then, the sum of the vascular occlusion score and perivascular
cellular infiltration score was designated as the vascular appearance
score.
FlowCytometry. Flow cytometric analysis was performed of spleen
and DLN, and each leukocyte population was quantified. All antibodies
were purchased from BD (BectonDickinson, Franklin Lakes, NJ). Cells
were run on a FACS Canto II (BD Bioscience, Franklin Lakes, NJ)
instrument. Data were analyzed by using FlowJo software.
DSA Assay. The level of circulating DSA-IgG in recipient mice
serum were assessed by flow cytometry. Recipient serum were
incubated with donor splenocytes at 37 °C for 30 min, washed, and
incubated with FITC-conjugated goat antibody specific for the Fc
portion of mouse IgG (Fc blocking antibody) at 4 °C for 1 h. After
being stained, the cells were washed, fixed in PBS containing 1%
formalin, and analyzed by flow cytometry as mean fluorescence
intensity to reflect individual serum DSA-IgG levels.
HUVEC Gene Expression Assessment.HUVEC were stimulated
by TNFα (10 ng/mL) and cultured in 6-well plates overnight (0.5 ×
106 cells/mL). Either PBS, free MMF, or MMF-NPs were added to the
HUVEC at concentrations similar to what was used in vivo. The samples
were incubated in a humidified 37 °C, 5% CO2 incubator in triplicates
for 24 h. Cells were washed three times with PBS, and the cell
suspension was analyzed by qPCR.
Elispot Assay. We followed the manufacturer’s instructions (BD
Biosciences). Immunospot plates (Millipore) were coated with IFNγ
primary antibody for 3 h at 37 °C. Donor (BM12) splenocytes were
irradiated at 3000 rads and plated with recipients’ (C57BL/6)
splenocytes in a 1:1 ratio and incubated in 37 °C for 24 h. Cells were
washed out, and the secondary antibody was added and incubated
overnight. After development with the chromogen, the total number of
spots per well were quantified using an ImmunoSpot Analyzer (Cellular
Technology, Cleveland, OH, USA).
Mixed Lymphocyte Reaction Assay. Irradiated donor (BM12)
splenocyte stimulators and recipient (C57BL/6) splenocyte responders
were added to each well in a 96-well round-bottom plate and incubated
at 37 °C for 2 days. An amount of 1 μCi of tritiated thymidine (3H) was
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added, and the plate was incubated for additional 14 h. The plate was
run on cell Harvester96, TOMTEC.
Quantitative PCR (qPCR). RNA was isolated with TRIZOL
(Invitrogen), and cDNA was synthesized using 2 μg of RNA and high-
capacity reverse transcriptase (Invitrogen). RT-PCR was performed
with SYBR Green PCR reagents on a Biorad detection system. RNA
levels were normalized to the level of GAPDH and calculated as delta−
delta threshold cycle (ΔΔCT). Primers used for RT-PCR are listed as
follows: GAPDH-F: GTTGTCTCCTGCGACTTCA, GAPDH-R:
GGTGGTCCAGGGTTTCTTA; IL2-F: TGAGCAGGATGGAGA-
ATTACAGG, IL2-R: GTCCAAGTTCATCTTCTAGGCAC, IL6-F:
CTCTGGGAAATCGTGGAAAT, IL6-R: CCAGTTTGGTAG-
CATCCATC, TNFα-F: ATGAGAAGTTCCCAAATGGC, TNFα-R:
CTCCACTTGGTGGTTTGCTA, IFNγ-F: TTGAGGTCAACAAC-
CCACAG, IFNγ-R: TCAGCAGCGACTCCTTTTC, IL17-F:
AAGGCAGCAGCGATCATCC, IL17-R: GGAACGGTTGAGGTA-
GTCTGAG, CCL2-F: GAAGGAATGGGTCCAGACAT, CCL2-R:
ACGGGTCAACTTCACATTCA, CCR2-F: ACACCCTGTTTCGC-
TGTAGG, CCR2-R: GATTCCTGGAAGGTGGTCAA, CCL5-F:
AGATCTCTGCAGCTGCCCTCA, CCL5-R: GGAGCAC-
TTGCTGCTGGTGTAG, CCR5-F: GCTGCCTAAACCCT-
GTCATC, CCR5-R: GTTCTCCTGTGGATCGGGTA, CXCL9-F:
CCGAGGCACGATCCACTAC, CXCL9-R: AGGCAGGTTTGAT-
CTCCGTT, CXCL10-F: CAAGTGCTGCCGTCATTTTCT,
CXCL10-R: ATAGGCTCGCAGGGATGATT, CXCR3-F:
TACCTTGAGGTTAGTGAACGTCA, CXCR3-R: CGCTCTC-
GTTTTCCCCATAATC. VCAM-F: GTCAAAGAACTAC-
AAGTCTA, VCAM-R: CTTCATTATCTAACTTCCTG, ICAM-F:
GCAGTGACTCTGTGTCAG, ICAM-R: GGATCTGGTCC-
GCTAGCTC, P-selectin-F: TCGGTACCTTGACGTACC, P-selec-
tin-R: CATGGATCCATTCTCAGG, hu-VCAM-F: CTACGCT-
GACAATGAATCCTG, hu-VCAM-R: GCAACTGAACACT-
TGACTGTG, hu-ICAM-F: CGTGTACTGGACTCCAGA, hu-
ICAM-R: CACCGTGGTCGTGACCTC, hu-P-selectin-F:
GCACTGACGGGTACCAAG, hu-P-selectin-R: TGCAGC-
TAGACTGATGCTG. All RT-PCR reactions were performed in
triplicate.
Statistics. Data analysis was performed by using GraphPad Prism
(GraphPad Software, Inc., San Diego, CA). Differences between groups
were evaluated by ANOVA to determine significance. Degrees of
significance were designated as *p < 0.05, **p < 0.01, and ***p < 0.001.
Data Availability. All data generated or analyzed during this study
are available from the corresponding author on reasonable request.
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